Marketing Approval For Photofrin In Japan

18 September 1994

Quadra Logic has received marketing approval in Japan for Photofrin (porfimer sodium) for a variety of indications including early-stage lung cancer, superficial esophageal cancer, early-stage gastric cancer and early-stage cervical cancer.

In addition, Quadra has reported that it has reaquired US and Canadian marketing rights to the drug from American Cyanamid, which is being taken over by American Home Products. The drug is scheduled for review by a Food and Drug Administration committee this month.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight